Georg-Speyer-Haus
The patent rights for using VPA in certain specified cancers, including Baceca® in skin cancer, have been in-licensed, on an exclusive basis, from the German Biomedical Research Institute Georg-Speyer-Haus. Under the licence agreement TopoTarget is obliged to pay low, single-digit percentage royalties based on net sales of future products derived from the patent.
|
About Us
Cancer